Elan Drug Technologies, the world?s leading drug delivery business, delivers clinically meaningful benefits to patients by using our extensive experience and proprietary delivery technologies in partnership with pharmaceutical companies to develop new and innovative products.
Elan Drug Technologies, the world’s leading drug delivery business, delivers clinically meaningful benefits to patients by using our extensive experience and proprietary delivery technologies in partnership with pharmaceutical companies to develop new and innovative products. With over 40 years experience in the drug delivery business, we have successfully brought 36 drugs to market for clients in over 100 markets. We have successful collaborations with the majority of the world’s leading pharma companies with client annual in-market sales of over $3 billion.
Drug optimization, development and manufacture
Elan has a unique platform of technologies to offer our clients - from oral controlled release, delayed release, pulsatile release delivery systems to technology solutions for poorly water soluble compounds. We have a complete range of capabilities from formulation development through to commercial scale manufacture in modern facilities. Our technologies are supported by a robust patent estate of over 1,900 patents / patent applications. Elan has developed unique capabilities to from early stage development right through to full scale final dosage form manufacture.
INVITATION TO MEET WITH US
Join us at CPhI Worldwide Annual meeting from October 5-7 in Paris where we will at booth location 5D63. To organise a meeting e-mail us at edtqueries@elan.com or check out our website to see the range of services we offer.
www.elandrugtechnologies.com
Clinical Supply Planning in Europe - Balancing Cost, Flexibility and Time
December 19th 2024The packaging and distribution of clinical supplies is a fundamental piece to the overall success of a clinical trial, and advance preparation can help establish a more efficient supply chain. Selecting the best geographical location for those activities, however, depends on the clinical trial protocol, business decisions, and even the investigational medicinal product (IMP) being studied.